This Cambridge startup is building a ‘foundation model’ for the chest to speed drug trials
THE SO WHAT
Qureight’s $20m bet on a single “foundation model for the chest” is vertical AI in its purest form—one high-fidelity model, many downstream lung and heart trial applications. If you’re in clinical or imaging-heavy domains, assume the competitive bar is shifting from point models per disease to shared backbones tuned for your organ system or modality.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureNothing Nefarious With 'Circle Financing': Dorrell
If Nvidia is working on more than $750B of AI-related deals and infra investors are normalizing structures like "circle financing," AI capex is becoming its own financial product. Operators should expect more creative, long-dated financing offers tied to compute usage—and read the fine print on control and lock-in.
Startups & VentureVC is changing dramatically — what’s a founder to do?
With capital concentrating into a narrow AI barbell, default-yes rounds are gone for most categories. Founders should underwrite plans on revenue, venture debt, and angels first—then treat traditional VC as opportunistic fuel, not the core power source.
Startups & VentureAI agents don’t log in like people. That problem just sold for $1bn.
A $1 billion acquisition for Oasis Security around AI agent identity is a clear price tag on the “non-human account” problem. If you’re spinning up agents that touch real data, you now need an IAM strategy for bots—credentials, lifecycle, and audit—on par with what you use for employees.
Robotics startup Generalist AI is in talks to raise a new funding round at a $3 billion valuation
A $3 billion valuation for a physical AI startup still in early deployment is a clear signal that capital is chasing general-purpose robotics as the next platform. If you're in logistics, manufacturing, or retail ops, start mapping which workflows could be addressable by humanoids or high-DOF robots within 24–36 months.